The Journal of Practical Medicine >

2023 , Vol. 39 >Issue 17: 2277 - 2279

DOI: https://doi.org/10.3969/j.issn.1006-5725.2023.17.022

Reviews

Research progress on relationship between cardiac amyloidosis and atrial fibrillation and its pathogenesis

  • Bo WU ,
  • Hengli LAI ,
  • Guowang SHEN ,
  • Zhenhuan CHEN ,
  • Yuan. LIU
Expand
  • *.Nanchang University Medical College，Nanchang 330000，China
    *.Jiangxi Provincial People′s Hospital，the First Affiliated Hospital of Nanchang Medical college，Nanchang 330000，China

Received date: 2023-06-13

  Online published: 2023-09-27

Fold

Abstract

Cardiac amyloidosis （CA） is a myocardial disease caused by extracellular deposition of misfolded amyloid proteins in the myocardium. CA is associated with a higher prevalence of atrial fibrillation （AF）， and myocardial amyloid infiltration can contribute to atrial electrical and structural remodeling through hemodynamic changes， increased ventricular wall stress， atrial amyloid deposition， and autonomic dysfunction， leading to the development and progression of AF. At present， the mechanism of CA in the pathogenesis of AF has not been elucidated. Therefore， exploring the relationship between CA and AF and the possible pathogenesis will help to deepen the knowledge of such patients and provide reference for clinical prevention and treatment.

Key words： cardiac amyloidosis; atrial fibrillation

Cite this article

Bo WU , Hengli LAI , Guowang SHEN , Zhenhuan CHEN , Yuan. LIU . Research progress on relationship between cardiac amyloidosis and atrial fibrillation and its pathogenesis[J]. The Journal of Practical Medicine, 2023 , 39(17) : 2277 -2279 . DOI: 10.3969/j.issn.1006-5725.2023.17.022

References

1 PAPATHANASIOU M， JAKSTAITE A M， OUBARI S， et al. Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis ［J］. ESC Heart Fail， 2022， 9（3）： 1740-1748.
2 杜美玲， 王晓元， 张爱爱， 等. 抗凝治疗与房颤患者血浆神经源性外泌体中T-tau蛋白和Aβ1-42含量变化的关系 ［J］. 实用医学杂志， 2022， 38（4）： 459-463.
3 VERGARO G， AIMO A， RAPEZZI C， et al. Atrial amyloidosis： mechanisms and clinical manifestations ［J］. Eur J Heart Fail， 2022， 24（11）： 2019-2028.
4 CAPPELLI F， TINI G， RUSSO D， et al. Arterial thrombo-embolic events in cardiac amyloidosis： a look beyond atrial fibrillation ［J］. Amyloid， 2021， 28（1）： 12-18.
5 BUKHARI S， BARAKAT A F， EISELE Y S， et al. Prevalence of Atrial Fibrillation and Thromboembolic Risk in Wild-Type Transthyretin Amyloid Cardiomyopathy ［J］. Circulation， 2021， 143（13）： 1335-1337.
6 ROSENBERG M A， MANNING W J. Diastolic dysfunction and risk of atrial fibrillation： a mechanistic appraisal ［J］. Circulation， 2012， 126（19）： 2353-2362.
7 LI G， YANG J， ZHANG D， et al. Research Progress of Myocardial Fibrosis and Atrial Fibrillation ［J］. Front Cardiovasc Med， 2022， 9： 889706.
8 DE JONG A M， VAN GELDER I C， VREESWIJK-BAUDOIN I， et al. Atrial remodeling is directly related to end-diastolic left ventricular pressure in a mouse model of ventricular pressure overload ［J］. PLoS One， 2013， 8（9）： e72651.
9 PACKER M， LAM C S P， LUND L H， et al. Interdependence of Atrial Fibrillation and Heart Failure With a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy ［J］. Circulation， 2020， 141（1）： 4-6.
10 ROSENBERG M A， GOTTDIENER J S， HECKBERT S R， et al. Echocardiographic diastolic parameters and risk of atrial fibrillation： the Cardiovascular Health Study ［J］. Eur Heart J， 2012， 33（7）： 904-912.
11 OSORIO-JARAMILLO E， COX J L， KLENK S， et al. Dynamic electrophysiological mechanism in patients with long-standing persistent atrial fibrillation ［J］. Front Cardiovasc Med， 2022， 9： 953622.
12 DE JONG A M， MAASS A H， OBERDORF-MAASS S U， et al. Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation ［J］. Cardiovasc Res， 2011， 89（4）： 754-765.
13 GUPTA D K， SHAH A M， GIUGLIANO R P， et al. Left atrial structure and function in atrial fibrillation： ENGAGE AF-TIMI 48 ［J］. Eur Heart J， 2014， 35（22）： 1457-1465.
14 YANG Z， SUBATI T， KIM K， et al. Natriuretic Peptide Oligomers Cause Proarrhythmic Metabolic and Electrophysiological Effects in Atrial Myocytes ［J］. Circ Arrhythm Electrophysiol， 2022， 15（3）： e010636.
15 RAHBAR KOUIBARAN F， SABATINO M， BAROZZI C， et al. Atrial Natriuretic Peptides as a Bridge between Atrial Fibrillation， Heart Failure， and Amyloidosis of the Atria ［J］. Int J Mol Sci， 2023， 24（7）： 6470.
16 黄江伟， 江鑫， 蒋长荣， 等. 心房肌细胞外泌体miR-130在房颤发病中的作用机制 ［J］. 实用医学杂志， 2022， 38（14）： 1766-1772.
17 PAZ P A， MANTILLA B D， ARGUETA E E， et al. Narrative review： the holy grail： update on pharmacotherapy for heart failure with preserved ejection fraction ［J］. Ann Transl Med， 2021， 9（6）： 523.
18 LEONE O， BORIANI G， CHIAPPINI B， et al. Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation ［J］. Eur Heart J， 2004， 25（14）： 1237-1241.
19 BUKHARI S， OLIVEROS E， PAREKH H， et al. Epidemiology， Mechanisms， and Management of Atrial Fibrillation in Cardiac Amyloidosis ［J］. Curr Probl Cardiol， 2023， 48（4）： 101571.
20 ROCKEN C， PETERS B， JUENEMANN G， et al. Atrial amyloidosis： an arrhythmogenic substrate for persistent atrial fibrillation ［J］. Circulation， 2002， 106（16）： 2091-2097.
21 HENEIN M Y， SUHR O B， ARVIDSSON S， et al. Reduced left atrial myocardial deformation irrespective of cavity size： a potential cause for atrial arrhythmia in hereditary transthyretin amyloidosis ［J］. Amyloid， 2018， 25（1）： 46-53.
22 LOHRMANN G， PATEL M A， BRAUNEIS D， et al. Left Atrial Mechanics Associates With Paroxysmal Atrial Fibrillation in Light-Chain Amyloidosis Following Stem Cell Transplantation ［J］. JACC CardioOncol， 2020， 2（5）： 721-731.
23 CHA T J， EHRLICH J R， ZHANG L， et al. Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure ［J］. Circulation， 2004， 109（3）： 412-418.
24 AGARWAL S K， NORBY F L， WHITSEL E A， et al. Cardiac Autonomic Dysfunction and Incidence of Atrial Fibrillation： Results From 20 Years Follow-Up ［J］. J Am Coll Cardiol， 2017， 69（3）： 291-299.
25 DEL MONTE A， PANNONE L， BISIGNANI A， et al. Cryoballoon ablation for atrial fibrillation： Effects on neuromodulation ［J］. Front Cardiovasc Med， 2022， 9： 958316.
26 CALKINS H， KUCK K H， CAPPATO R， et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation： recommendations for patient selection， procedural techniques， patient management and follow-up， definitions， endpoints， and research trial design ［J］. J Interv Card Electrophysiol， 2012， 33（2）： 171-257.
27 WHITE C M， SANDER S， COLEMAN C I， et al. Impact of epicardial anterior fat pad retention on postcardiothoracic surgery atrial fibrillation incidence： the AFIST-III Study ［J］. J Am Coll Cardiol， 2007， 49（3）： 298-303.
28 MENTIAS A， ALVAREZ P， CHAUDHURY P， et al. Direct Oral Anticoagulants in Cardiac Amyloidosis-Associated Heart Failure and Atrial Fibrillation ［J］. Am J Cardiol， 2022， 164： 141-143.
29 朱业， 刘佳， 谷慧阳， 等. 基因检测指导下非瓣膜性房颤患者华法林抗凝治疗的研究 ［J］. 实用医学杂志， 2021， 37（18）： 2355-2359.
30 MINTS Y Y， DOROS G， BERK J L， et al. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis： a systematic review and clinical experience ［J］. ESC Heart Fail， 2018， 5（5）： 772-779.
Options
Outlines

/

〈 〉